# Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)

> **NCT03189433** · PHASE2 · TERMINATED · sponsor: **Eagle Pharmaceuticals, Inc.** · enrollment: 2 (actual)

## Conditions studied

- Drug Toxicity Psychotropic Agents Psychostimulants

## Interventions

- **DRUG:** Ryanodex (dantrolene sodium) for injectable suspension

## Key facts

- **NCT ID:** NCT03189433
- **Lead sponsor:** Eagle Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-12
- **Primary completion:** 2018-12-31
- **Final completion:** 2018-12-31
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Limited enrollment
- **Last updated:** 2021-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03189433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03189433, "Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03189433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*